Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Roffi, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Roffi, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Early invasive strategy in the diabetic patient with non-ST-segment elevation acute coronary syndromes

Marco Roffi*

Division of Cardiology, University Hospital, Zurich, Switzerland

* Corresponding author. Tel: +41 1 255 8573; fax: +41 1 255 4401. E-mail address: marco.roffi{at}usz.ch

Diabetic patients with non-ST-segment elevation acute coronary syndromes are at high risk for subsequent cardiovascular events. At the same time, however, they derive greater benefit than non-diabetic counterparts from an aggressive acute-phase management based on platelet glycoprotein IIb/IIIa receptor antagonists and an early invasive strategy. Despite the benefit, these treatment modalities remain underutilized among patients with diabetes mellitus. The widespread use of drug-eluting stents will further improve outcomes in patients with diabetes undergoing early percutaneous revascularization. In this patient population, the sirolimus-eluting stent appears to be superior to the paclitaxel-coated one.

Key Words: Diabetes mellitus • Acute coronary syndromes • Early invasive strategy • Glycoprotein IIb/IIIa receptor inhibitors • Drug-eluting stents


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.